Entrada Therapeutics (TRDA) Stock Analysis & AI Equity Report
Entrada Therapeutics (TRDA) overview
Entrada Therapeutics (TRDA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 25.4m and operating profit of USD -158m; the year-end share price was 10.28 USD and market capitalisation was USD 394m. Entrada Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Entrada Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines intended to engage intracellular targets. Its development portfolio includes programs for neuromuscular and inherited retinal diseases, with several clinical programs for Duchenne muscular dystrophy patients eligible for exon-skipping approaches. The company is also partnered with Vertex Pharmaceuticals on VX-670, a program for myotonic dystrophy type 1. Its medicines remain in clinical development.
Generate the Entrada Therapeutics report
Entrada Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Entrada Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Entrada Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.